The information in the below press release is intended for investors.

Posts tagged with ‘disclaimer’

  • Isofol announces start of study data analysis of phase III AGENT study in advanced metastatic colorectal cancer

    GOTHENBURG, Sweden, April 22, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced the start of data analysis…

    by
  • Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision

    GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and…

    by
  • Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)

    GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and Drug…

    by
  • Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm

    GOTHENBURG, Sweden, October 18, 2021 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the…

    by
  • Isofol completes recruitment of Japanese patients in the global phase III AGENT study

    GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market:…

    by
  • Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million

    GOTHENBURG, Sweden, April 28, 2021 - Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that…

    by
  • Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved

    GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that…

    by
  • Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients

    GOTHENBURG, Sweden, March 22, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announced on…

    by
  • Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients

    GOTHENBURG, Sweden, March 19, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by
  • Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

    GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by